http://www.endless5dollarpayments.com
ORLANDO, Fla. — The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with bullous pemphigoid (BP), a phase 2/3 study demonstrated. “Dupilumab demonstrated significant benefits across multiple disease aspects in BP at 36 weeks...
Copyright © 2024omega1medianewsglobalnetwork. All Rights Reserved http://www.endless5dollarpayments.com
